Dissociation between biochemical and behavioral recovery in MPTP-treated mice

Pharmacol Biochem Behav. 1989 Sep;34(1):113-7. doi: 10.1016/0091-3057(89)90362-6.

Abstract

Injection of a low dose of haloperidol, that has no obvious behavioral effects in normal mice, produces akinesia, catalepsy, and somatosensory neglect in MPTP-treated mice. These neuroleptic-induced sensorimotor impairments are exhibited soon after MPTP treatments and coincide with a decrease in both striatal DA and DOPAC levels. DA and DOPAC content gradually return to near-control levels over a 3-5 month period. Interestingly, while the haloperidol-induced somatosensory deficits declined in parallel with the rise in DA and DOPAC levels, the motor deficits persisted for up to 5 months after MPTP administration. These data suggest subtle differences in the neurochemical mediation of these behaviors and that the persistence of neuronal impairments may not necessarily be revealed by near-normal transmitter levels.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology*
  • 3,4-Dihydroxyphenylacetic Acid / analysis*
  • Animals
  • Benzazepines / pharmacology
  • Corpus Striatum / analysis*
  • Corpus Striatum / drug effects
  • Dopamine / analysis*
  • Dopamine Antagonists
  • Drug Interactions
  • Haloperidol / pharmacology*
  • Male
  • Mice
  • Phenylacetates / analysis*
  • Psychomotor Performance / drug effects*
  • Sulpiride / pharmacology
  • Time Factors

Substances

  • Benzazepines
  • Dopamine Antagonists
  • Phenylacetates
  • 3,4-Dihydroxyphenylacetic Acid
  • Sulpiride
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Haloperidol
  • Dopamine